Chicago—New clinical recommendations from the North American Menopause Society (NAMS) show that many physicians are left with more questions than answers following the recent release of data from two large clinical trials of hormone replacement therapy (HRT).
After the publication of follow-up findings from the Heart and Estrogen/progestin Replacement Study (HERS II) and a halted arm of the Women's Health Initiative (WHI), the NAMS board faced two issues: whether to respond to the findings and, if so, how best to guide clinicians who prescribe HRT.
Voelker R. Questions About Hormone Therapy Remain Puzzling. JAMA. 2002;288(19):2395-2396. doi:10.1001/jama.288.19.2395-JMN1120-2-1